A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Clinical trial NCT02852655 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02852655
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-21
- Primary completion
- 2022-06-02
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.